Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Up to 45% of patients may have persistently elevated parathyroid hormone (PTH) levels after curative parathyroidectomy for primary hyperparathyroidism (PHPT), although the clinical significance is unclear. We aimed to assess the long-term clinical significance of persistently elevated PTH early after parathyroidectomy.
Methods: A prospectively collected institutional database was queried for patients who underwent parathyroidectomy for sporadic PHPT between 12/99 and 6/22 and had normal serum calcium levels at 6 months postoperatively. Demographic and clinical data were collected, including diagnoses associated with secondary HPT (gastrointestinal malabsorptive diseases, kidney disease, and vitamin D deficiency). Patients were divided into two groups: normal PTH or elevated PTH at 6 months postoperatively. The rate of persistently elevated PTH, average time to PTH normalization, and time to recurrence were determined.
Results: The final cohort included 1146 patients; 849 (91%) had normal PTH levels and 194 (17%) had early postoperative normocalcemia with elevated PTH at 6 months postoperatively. Among 194 patients (mean follow-up: 50 ± 53 months), 14 (7.2%) developed recurrent pHPT and 86 (44.3%) had normalization of PTH levels (median time to normalization: 12 months) (IQR: 9 and 15). There was no difference in the presence of diagnoses associated with secondary HPT between patients who had recurrent PHPT, normalization of PTH levels, or remained normocalcemic with persistently elevated PTH levels. The median time to recurrence was 22 months (IQR: 11 and 48) for the 7.2% of patients who developed recurrent PHPT compared to 2.4% in the 849 patients with normal calcium and PTH levels at 6 months (p < 0.001).
Conclusions: Following curative parathyroidectomy, persistent elevation of PTH levels is not uncommon. Although most patients have a durable cure, it may be an early sign of persistent/recurrent PHPT. Long-term surveillance for recurrence is necessary.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/wjs.12413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating Vitamin D Deficiency-Linked Digestive Issues by Bridging Endocrinology With Gastrointestinal Disorders.
Cureus
August 2025
Biochemistry, Liaquat University of Medical and Health Sciences, Karachi, PAK.
Background: Vitamin D insufficiency is increasingly recognized as a significant and underlying contributor to a wide range of musculoskeletal disorders, particularly in gastrointestinal (GI) and endocrine health. The study aims to determine the clinical relationship between vitamin D status and the severity of GI symptoms, while also assessing the impact of related endocrine disturbances.
Methods: A cross-sectional study was conducted involving 120 adult patients with GI problems, including constipation, bloating, irritable bowel syndrome (IBS), and dyspepsia in a tertiary care hospital over a six-month duration.
The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans-a histomorphometry centered scoping review.
Osteoporos Int
September 2025
Molecular Bone Histology Lab, Research Unit of Pathology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Intermittent PTH treatment has been used as both an osteoanabolic treatment in osteoporosis and a hormone replacement in hypoparathyroidism for many years. This scoping review compiles and reinterprets studies using histomorphometry supported by bone turnover markers to investigate the elusive cellular effect of intermittent PTH treatment locally within the bone, while illuminating knowledge gaps. Intermittent PTH increases both osteoclast and osteoblast activity within the first 6 months of treatment.
View Article and Find Full Text PDFA presentation of brown tumor in a patient with parathyroid adenoma and end-stage renal disease: A case report.
Medicine (Baltimore)
September 2025
Department of Internal Medicine, Lahore General Hospital, Lahore, Punjab, Pakistan.
Rationale: Brown tumor (osteitis fibrosa cystica) is a benign bone lesion associated with hyperparathyroidism that can affect multiple bones in patients with end-stage renal disease (ESRD).
Patient Concerns: We present the case of a 32-year-old female with ESRD on maintenance hemodialysis who experienced body aches, muscle weakness, constipation, and mood swings for 3 months.
Diagnoses: Initial tests revealed elevated parathyroid hormone (PTH), serum calcium, and phosphorus levels.
A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.
Endocrinol Diabetes Metab Case Rep
July 2025
Department of Internal Medicine, Medical City Arlington, Arlington, Texas, USA.
Summary: Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia. Tirzepatide, a dual GIP and GLP-1 receptor agonist, is increasingly used for type 2 diabetes and obesity.
View Article and Find Full Text PDFCorrelation between thyroid sensitivity indices and bone metabolism in newly diagnosed middle aged and elderly patients with type 2 diabetes mellitus with normal thyroid function.
BMC Endocr Disord
September 2025
Department of Endocrinology and Metabolism, Jiangxi Medical College, The Second Affiliated Hospital, Nanchang University, Nanchang City, 330006, Jiangxi Province, China.
Objective: To investigate the association between thyroid hormone sensitivity indices and bone metabolism markers in newly diagnosed middle-aged and elderly type 2 diabetes mellitus (T2DM) patients with normal thyroid function.
Method: We retrospectively analyzed 350 newly diagnosed T2DM patients (≥ 45 years), stratified by bone mineral density into Group A (normal bone density group) and Group B (low bone mass and osteoporosis group). General data and clinical biochemical parameters were collected: free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), osteocalcin (OC), bone-specific alkaline phosphatase (BALP), serum calcium (Ca), serum phosphorus (P), fasting plasma glucose (FPG), glycosylated hemoglobinA1c (HbA1c), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), serum creatinine (SCr), serum uric acid (SUA), and estimated Glomerular Filtration Rate (eGFR).